ABBV•benzinga•
AbbVie And Xilio Therapeutics Announced A Collaboration And Option-to-license Agreement To Develop Novel Tumor-activated, Antibody-based Immunotherapies, As Per Which Xilio Will Receive $52.0M In Total Upfront Payments And Be Eligible To Receive Up To Aro
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga